Relapsed Ewing Sarcoma
Conditions
Keywords
Relapsed Ewing sarcoma, bromodomain-containing protein (BRD) inhibitor, lysine demethylase 1 (LSD1) inhibitor
Brief summary
The purpose of this study is to evaluate the safety and preliminary antitumor activity of INCB059872 in participants with Ewing sarcoma who are refractory or relapsed from prior standard therapy and not eligible for further standard systemic therapy.
Interventions
DRUGINCB059872
Part 1: Initial cohort of INCB059872 administered every other day (QOD) at the protocol-defined starting dose, with subsequent cohort dose escalation based on protocol-defined criteria. Part 2: Expansion with the recommended dose from Part 1.
Sponsors
Incyte Corporation
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed diagnosis of Ewing sarcoma and have progressed on or after standard therapies. * Must not be a candidate for potentially curative therapy or standard-of-care approved therapy. * Measurable disease by computed tomography or magnetic resonance imaging based on RECIST 1.1 as determined by site radiology. * Eastern Cooperative Oncology Group performance status 0 to 2. * Willingness to avoid pregnancy or fathering children.
Exclusion criteria
* Receipt of anticancer medications, anticancer therapies, or investigational drugs within protocol-defined intervals before the first administration of study drug. * Must have recovered (≤ Grade 2 or at pretreatment baseline) from adverse events (AEs) from previously administered therapies except for stable chronic toxicities (≤ Grade 2) not expected to resolve. * Untreated brain or central nervous system (CNS) metastases or brain/CNS metastases that have progressed. * Prior radiotherapy within 2 weeks of study treatment. A 1-week washout period is permitted for palliative radiation to non-CNS disease with medical monitor approval. * Laboratory values outside the protocol-defined range at screening. * History or evidence of bleeding disorder or active clinically significant bleeding requiring medical intervention.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of adverse events | Screening through 30 days after last dose of study treatment, up to approximately 6 months. | Defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of a drug in humans, whether or not considered drug-related. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate | Up to approximately 6 months. | Defined as the percentage of participants who have a complete response or partial response as determined by investigator assessment of response per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. |
| Cmax of INCB059872 | Up to approximately 2 weeks. | Defined as maximum observed plasma concentration. |
| tmax of INCB059872 | Up to approximately 2 weeks. | Defined as time to maximum concentration. |
| t½ of INCB059872 | Up to approximately 2 weeks. | Defined as apparent terminal-phase disposition half-life. |
| Cl/F of INCB059872 | Up to approximately 2 weeks. | Defined as apparent oral dose clearance. |
Countries
Italy, Spain, United Kingdom, United States
Outcome results
None listed